

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert Proulx
<b>Date of last notice</b>	22 October 2020

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	17 November 2021

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 5,987,000 Ordinary Shares</li> <li>2) 5,000,000 Performance Rights</li> <li>3) 176,250 Listed IBXO options (exercisable at \$0.05, expiring on 26 November 2021)</li> <li>4) 282,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>5) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>6) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> <li>7) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)</li> </ol>
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	1) 176,250
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1) \$8,812.50
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1) 6,163,250 Ordinary Shares</li> <li>2) 5,000,000 Performance Rights</li> <li>3) Nil Listed IBXO options (exercisable at \$0.05, expiring on 26 November 2021)</li> <li>4) 282,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>5) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>6) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> <li>7) 2,000,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2023, expiring 1 May 2028)</li> </ol>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Listed IBXO Options
---	---------------------------------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Ludvigson
<b>Date of last notice</b>	11 August 2020

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	19 November 2021
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1) 470,000 Ordinary Shares</li> <li>2) 75,000 Listed IBXO options (exercisable at \$0.05, expiring on 26 November 2021)</li> <li>3) 120,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023)</li> <li>4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026)</li> <li>5) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)</li> </ol>
<b>Class</b>	Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	1) 75,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1) \$3,750
<b>No. of securities held after change</b>	1) 545,000 Ordinary Shares 2) Nil Listed IBXO options (exercisable at \$0.05, expiring on 26 November 2021) 3) 120,000 Listed IBXOA options (exercisable at \$0.03, expiring on 28 April 2023) 4) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2021, expiring 1 May 2026) 5) 250,000 Unlisted Performance Options (exercisable at \$0.028, vesting on 1 May 2022, expiring 1 May 2027)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of Listed IBXO Options

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.